The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
IntroductionSoluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cell...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1194315/full |
| _version_ | 1797623767440031744 |
|---|---|
| author | Sang Eun Yoon Sujin Park Junhun Cho Kyung Ju Ryu Booma Yandava Sewon Lee Seok Jin Kim Won Seog Kim |
| author_facet | Sang Eun Yoon Sujin Park Junhun Cho Kyung Ju Ryu Booma Yandava Sewon Lee Seok Jin Kim Won Seog Kim |
| author_sort | Sang Eun Yoon |
| collection | DOAJ |
| description | IntroductionSoluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cell lymphoma (ND-DLBCL).MethodsWe analyzed sMICA/sMICB, cytokine in serum, and macrophage polarization analysis in tissue samples before the first chemotherapy administration. This research was performed to investigate the correlation between sMICA/sMICB expression and treatment outcomes as well as their influence on the immune system within ND-DLBCL.ResultsOf the 262 patients, 47.3% (n = 124) presented stage III or IV at diagnosis and 50.8% (n = 133) had a high International Prognostic Index (IPI ≥ 3). The patients with high (p = 0.034 and 0.004), elevated lactate dehydrogenase (p = 0.002 and 0.030), advanced stage (p = 0.003 and 0.012), and higher IPI risk (p = 0.009, and 0.032) correlated with the detection of sMICA or sMICB. The median progression-free survival (PFS) of patients with sMICA (p = 0.006) or sMICB (p =0.032) was inferior. Among the patients with advanced-stage or high IPI, those with sMICA or sMICB presented an inferior PFS and OS compared to those without. TNF-a, a pro-inflammatory cytokine, showed statistical significance with detected sMICA (p = 0.035) or sMICB (p = 0.044). Among anti-inflammatory cytokines, IL-1RA (P-value = 0.013) and IL-10 (p = 0.005) were associated with detecting sMICB, but not sMICA. In tissue samples, sMICA or sMICB detection did not correlate with the CD68/CD163 ratio.DiscussionConclusively, the identification of sMICA/sMICB presented unfavorable immunochemotherapy outcomes, and it was assumed that sMICA or sMICB and various cytokines interact, but the relationship with macrophage differentiation is unclear. Therefore, further research is needed to determine the relationship between sMICA/sMICB and tumor microenvironment in DLBCL. |
| first_indexed | 2024-03-11T09:33:26Z |
| format | Article |
| id | doaj.art-745c8b0762bd4e0ab1222c844cf50db1 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T09:33:26Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-745c8b0762bd4e0ab1222c844cf50db12023-11-16T17:28:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-11-011310.3389/fonc.2023.11943151194315The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphomaSang Eun Yoon0Sujin Park1Junhun Cho2Kyung Ju Ryu3Booma Yandava4Sewon Lee5Seok Jin Kim6Won Seog Kim7Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of KoreaSamyang Biopharm USA, Cambridge, MA, United StatesDivision of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaIntroductionSoluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cell lymphoma (ND-DLBCL).MethodsWe analyzed sMICA/sMICB, cytokine in serum, and macrophage polarization analysis in tissue samples before the first chemotherapy administration. This research was performed to investigate the correlation between sMICA/sMICB expression and treatment outcomes as well as their influence on the immune system within ND-DLBCL.ResultsOf the 262 patients, 47.3% (n = 124) presented stage III or IV at diagnosis and 50.8% (n = 133) had a high International Prognostic Index (IPI ≥ 3). The patients with high (p = 0.034 and 0.004), elevated lactate dehydrogenase (p = 0.002 and 0.030), advanced stage (p = 0.003 and 0.012), and higher IPI risk (p = 0.009, and 0.032) correlated with the detection of sMICA or sMICB. The median progression-free survival (PFS) of patients with sMICA (p = 0.006) or sMICB (p =0.032) was inferior. Among the patients with advanced-stage or high IPI, those with sMICA or sMICB presented an inferior PFS and OS compared to those without. TNF-a, a pro-inflammatory cytokine, showed statistical significance with detected sMICA (p = 0.035) or sMICB (p = 0.044). Among anti-inflammatory cytokines, IL-1RA (P-value = 0.013) and IL-10 (p = 0.005) were associated with detecting sMICB, but not sMICA. In tissue samples, sMICA or sMICB detection did not correlate with the CD68/CD163 ratio.DiscussionConclusively, the identification of sMICA/sMICB presented unfavorable immunochemotherapy outcomes, and it was assumed that sMICA or sMICB and various cytokines interact, but the relationship with macrophage differentiation is unclear. Therefore, further research is needed to determine the relationship between sMICA/sMICB and tumor microenvironment in DLBCL.https://www.frontiersin.org/articles/10.3389/fonc.2023.1194315/fulltumor microenvironmentnatural killer group 2 member DMHC class I-related chain AMHC class I-related chain Bnewly diagnosed diffuse large B-cell lymphoma |
| spellingShingle | Sang Eun Yoon Sujin Park Junhun Cho Kyung Ju Ryu Booma Yandava Sewon Lee Seok Jin Kim Won Seog Kim The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma Frontiers in Oncology tumor microenvironment natural killer group 2 member D MHC class I-related chain A MHC class I-related chain B newly diagnosed diffuse large B-cell lymphoma |
| title | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
| title_full | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
| title_fullStr | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
| title_full_unstemmed | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
| title_short | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
| title_sort | impact of smica smicb on immunochemotherapy outcomes in newly diagnosed diffuse large b cell lymphoma |
| topic | tumor microenvironment natural killer group 2 member D MHC class I-related chain A MHC class I-related chain B newly diagnosed diffuse large B-cell lymphoma |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1194315/full |
| work_keys_str_mv | AT sangeunyoon theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT sujinpark theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT junhuncho theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT kyungjuryu theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT boomayandava theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT sewonlee theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT seokjinkim theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT wonseogkim theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT sangeunyoon impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT sujinpark impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT junhuncho impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT kyungjuryu impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT boomayandava impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT sewonlee impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT seokjinkim impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT wonseogkim impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma |